Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Phase 2
Recruiting
- Conditions
- Nasopharyngeal CarcinomaNasopharyngeal Cancer
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04978012
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
Early Phase 1
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Combination Product: PD-1 and Lenvatinib Plus TACE
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04974281
- Locations
- 🇨🇳
Huashan hospital, Shanghai, Shanghai, China
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Phase 2
- Conditions
- Effect of DrugGastrointestinal Tumor
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04960943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
TACE Combined with Tislelizumab in Patients with Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Combination Product: TACE
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT04954781
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Combination Product: TACE
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 29
- Registration Number
- NCT04954794
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
- Conditions
- Cancer of Unknown Primary Site
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT04952103
- Locations
- 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Phase 2
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT04948034
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast CancerBone Metastases
- Interventions
- Radiation: Fractionated Stereotatic Radiation Therapy
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04947280
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
- Conditions
- Neuroendocrine Neoplasm
- Interventions
- Procedure: Biopsy, open or laparoscopic surgery
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT04927611
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 356
- Registration Number
- NCT04922008
© Copyright 2025. All Rights Reserved by MedPath